315. Shahab Elmi, Co-Founder & CEO of Cymbiotika

Today, I'm joined by Shahab Elmi, co-founder & CEO of Cymbiotika. With 100M+ packets sold in its first six years, Cymbiotika is bringing transparency to the supplement industry with liposomal formulations and rigorous third-party testing. In this episode, we discuss building a supplement brand focused on efficacy over marketing. We also cover: Liposomal delivery as a differentiator Why churn reveals true product efficacy Avoiding the wellness DTC race to the bottom    Subscribe to the podcast → insider.fitt.co/podcast   Subscribe to our newsletter → insider.fitt.co/subscribe   Follow us on LinkedIn → linkedin.com/company/fittinsider    Cymbiotika's Website: www.cymbiotika.com  Cymbiotika's Instagram: https://www.instagram.com/cymbiotika/  - The Fitt Insider Podcast is brought to you by EGYM. Visit EGYM.com to learn more about its smart fitness ecosystem for fitness and health facilities. Fitt Talent: https://talent.fitt.co/  Consulting: https://consulting.fitt.co/  Investments: https://capital.fitt.co/   Chapters:  (00:00) Introduction  (01:15) Shahab's background and Cymbiotika's origin story  (02:00) The problem with the supplement industry  (02:45) Why transparency and testing matter  (04:15) Churn rate as the ultimate success metric  (05:45) Organic celebrity endorsements vs paid sponsorships  (09:00) Liposomal delivery technology explained  (12:30) Manufacturing in-house vs outsourcing  (16:00) The DTC race to the bottom  (18:30) Building trust through radical transparency  (20:30) Competing on efficacy, not marketing spend  (23:00) Taking on industry fraud and fake claims  (24:30) Announcing multiple third-party clinical trials  (26:50) Patent enforcement and liposome validation  (27:35) Product roadmap (29:25) Conclusion